 Applied Therapeutics, Inc. APLT, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced additional supportive biomarker efficacy and safety data for AT-007 in Galactosemia at 40 mgkg. From a scientific perspective, it was important to investigate effects of AT-007 at the higher dose, 40mgkg, to ensure that we are fully informed on the optimal dose for patients, said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. 